Reported 2 days ago
President-elect Trump's nomination of Robert F. Kennedy Jr. as Secretary of Health and Human Services has raised alarm regarding his critical views on the pharmaceutical industry and GLP-1 drugs. Analysts express worries about Kennedy's inexperience in executive roles impacting policy advancements, particularly with Medicare coverage. However, some suggest that the recent declines in pharmaceutical stocks may be exaggerated.
Source: YAHOO